Literature DB >> 17569629

Hepsin and prostate cancer.

Qingyu Wu1, Gordon Parry.   

Abstract

Hepsin is a membrane serine protease expressed in several human tissues including the liver, kidney, prostate, and thyroid. The physiological function of hepsin remains unknown. In vitro studies have shown that hepsin activates blood clotting factors VII, XII, and IX, pro-urokinase (pro-uPA), and pro-hepatocyte growth factor (pro-HGF). Recently, hepsin has been identified as one of the most up-regulated genes in prostate cancer. The hepsin up-regulation appears to correlate with the disease progression. In a mouse model of prostate cancer, hepsin overexpression promotes cancer progression and metastasis. In culture, anti-hepsin antibodies inhibited the invasion of human prostate cancer cells. This review will outline the molecular biology and biochemistry of hepsin and highlight recent data of hepsin in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569629     DOI: 10.2741/2447

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  23 in total

Review 1.  Type II transmembrane serine proteases.

Authors:  Thomas H Bugge; Toni M Antalis; Qingyu Wu
Journal:  J Biol Chem       Date:  2009-06-01       Impact factor: 5.157

2.  Urokinase-controlled tumor penetrating peptide.

Authors:  Gary B Braun; Kazuki N Sugahara; Olivia M Yu; Venkata Ramana Kotamraju; Tarmo Mölder; Andrew M Lowy; Erkki Ruoslahti; Tambet Teesalu
Journal:  J Control Release       Date:  2016-04-19       Impact factor: 9.776

Review 3.  The role of type II transmembrane serine protease-mediated signaling in cancer.

Authors:  Lauren M Tanabe; Karin List
Journal:  FEBS J       Date:  2016-12-24       Impact factor: 5.542

Review 4.  Corin in clinical laboratory diagnostics.

Authors:  Ningzheng Dong; Shenghan Chen; Wei Wang; Yiqing Zhou; Qingyu Wu
Journal:  Clin Chim Acta       Date:  2011-11-07       Impact factor: 3.786

5.  Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.

Authors:  Srinivas Nandana; Katharine Ellwood-Yen; Charles Sawyers; Marcia Wills; Brandy Weidow; Thomas Case; Valeri Vasioukhin; Robert Matusik
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

6.  Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.

Authors:  Manisha Tripathi; Srinivas Nandana; Hironobu Yamashita; Rajkumar Ganesan; Daniel Kirchhofer; Vito Quaranta
Journal:  J Biol Chem       Date:  2008-09-09       Impact factor: 5.157

7.  Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses.

Authors:  Wataru Komaki; Tsuyoshi Fukushima; Hiroyuki Tanaka; Hiroshi Itoh; Etsuo Chosa; Hiroaki Kataoka
Journal:  Virchows Arch       Date:  2008-09-04       Impact factor: 4.064

8.  Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer.

Authors:  Aaron M LeBeau; Sangeeta R Banerjee; Martin G Pomper; Ronnie C Mease; Samuel R Denmeade
Journal:  Bioorg Med Chem       Date:  2009-06-13       Impact factor: 3.641

9.  Association of hepsin gene variants with prostate cancer risk and prognosis.

Authors:  Sarah K Holt; Erika M Kwon; Daniel W Lin; Elaine A Ostrander; Janet L Stanford
Journal:  Prostate       Date:  2010-06-15       Impact factor: 4.104

Review 10.  Membrane-anchored serine proteases in health and disease.

Authors:  Toni M Antalis; Thomas H Bugge; Qingyu Wu
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.